Relation of Functional Activity of Platelets to Prognosis of Unfavorable Cardiovascular Events in Patients with Acute Coronary Syndrome. Results of a Registry Study

Aim: to assess relation ofhigh functional activity ofplatelets to prognosis ofunfavorable cardiovascular events in patients with Acute Coronary Syndrome (ACS).

Materials. The study was based on the data of a single center ACS registry conducted in the Central Clinical Hospital of the Presidential Affairs Department of Russian Federation. Of 529 included patients in 425 without contraindications to double antiplatelet therapy we carried out analysis of dependence of 30 days level of unfavorable events on parameters of functional activity of platelets.

Results. High on-treatment platelet reactivity (HTPR) was found to be associated with 3.5 increase of mortality in the group of patients with high cardiovascular risk. Logistic model of prognosis of unfavorable events based on multifactorial analysis of data from patients with measured platelet aggregation included chronic kidney disease, type of myocardial infarction, and degree ofplatelet aggregation >45%. C -statistic was equal to 0.77. We also present in this paper discussion of problems related to studying approaches to individualization of anti-aggregation therapy in real clinical practice and problems of organization ofsimilar studies.

Conclusion. The study showed that patients with ACS increased platelet aggregation, as well as chronic kidney disease and type 2 MI are associated with a 30 day prognosis of adverse events.

1. Breet NJ. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA. 2010;303(8):754-62. DOI: 10.1001/jama.2010.181

2. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A et al. Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology. 2009;53(10):849-56. DOI: 10.1016/j.jacc.2008.11.030

3. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F-J, Metzger DC et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. The Lancet. 2013;382(9892):614-23. DOI: 10.1016/S0140-6736(13)61170-8

4. Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R et al. Predictive Values of Post-Treatment Adenosine Diphosphate-Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. The AmericanJ ournal of Cardiology. 2009;104(8):1078-82. DOI: 10.1016/j.amjcard.2009.06.007

5. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B et al. High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI. JAMA. 2011;306(11):1215-23. DOI: 10.1001/jama.2011.1332

6. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal. 2006;27(20):2420-5. DOI: 10.1093/eurheartj/ehl275

7. Hochholzer W, Trenk D, Bestehorn H-P, Fischer B, Valina CM, Ferenc M et al. Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement. Journal of the American College of Cardiology. 2006;48(9):1742-50. DOI: 10.1016/j.jacc.2006.06.065

8. Angiolillo DJ, Bernardo E, Sabate M,Jimenez-Quevedo P, Costa MA, Palazuelos J et al. Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology. 2007;50(16):1541-7. DOI: 10.1016/j.jacc.2007.05.049

9. Gurbel PA, Antonino MJ, Bliden KP, DiChiara J, Suarez TA, Singla A et al. Platelet reactivity to adenosine diphosphate and longterm ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets. 2008;19(8):595-604. DOI: 10.1080/09537100802351065

10. Lordkipanidze M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. European Heart Journal. 2008;29(23):2877-85. DOI: 10.1093/eurheartj/ehn419

11. Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis. 2013;11(6):1183-9. DOI: 10.1111/jth.12231

12. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman ^A, Kreutz RP et al. Platelet Reactivity in Patients and Recurrent Events Post-Stenting. Journal of the American College of Cardiology. 2005;46(10):1820-6. DOI: 10.1016/j.jacc.2005.07.041

13. Peace AJ, Egan K, Kavanagh GF, Tedesco AF, Foley DP, Dicker P et al. Reducing intra-individual variation in platelet aggregation: implications for platelet function testing. Journal of Thrombosis and Haemostasis. 2009;7(11):1941-3. DOI: 10.1111/j.1538-7836.2009.03593.x

14. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for CoronaryStenting: Response Variability, DrugResistance, andtheEffect of Pretreatment Platelet Reactivity. Circulation. 2003;107(23):2908-13. DOI: 10.1161/01.CIR.0000072771.11429.83

15. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2011;32(23):2999-3054. DOI: 10.1093/eurheartj/ehr236

16. Authors/Task Force Members, Steg PhG, James SK, Atar D, Badano LP, Lundqvist CB et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012;33(20):2569-619. DOI: 10.1093/eurheartj/ehs215

17. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third Universal Definition of Myocardial Infarction. Circulation. 2012;126(16):2020-35. DOI: 10.1161/CIR.0b013e31826e1058

18. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-51. DOI: 10.1161/CIRCULATIONAHA.106.685313

19. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449

20. Hayward CPM, Moffat ^A, Raby A, Israels S, Plumhoff E, Flynn G et al. Development of North American Consensus Guidelines for Medical Laboratories That Perform and Interpret Platelet Function Testing Using Light Transmission Aggregometry. American Journal of Clinical Pathology. 2010;134(6):955-63. DOI: 10.1309/AJCP9V3RRVNZMKDS

21. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities. 2001;L121:34-44. [Av. at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32001L0020]

22. Serebruany VL, Gurbel PA, Shustov AR, Ohman EM, Topol EJ. Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. American Heart Journal. 1998;136(3):398-405. DOI: 10.1016/S0002-8703(98)70212-1

23. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp C. Comparison of methods to evaluate clopidogrel-mediat-ed platelet inhibition after percutaneous intervention with stent implantation. Thrombosis and Haemostasis. 2009;101(02):333-9. DOI: 10.1160/TH08-09-0577

24. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets. 2011;22(3):188-95. DOI: 10.3109/09537104.2010.543963

25. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology. 2005;45(2):246-51. DOI: 10.1016/j.jacc.2004.09.067

26. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thrombosis and Haemostasis. 2011;106(08):211-8. DOI: 10.1160/TH11-03-0137

27. Valgimigli M, Bueno H, Byrne ^A, Collet J-P, Costa F, Jeppsson A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery. 2018;53(1):34-78. DOI: 10.1093/ejcts/ezx334

28. Levine GN, Bates ER, BittlJA, Brindis RG, Fihn SD, Fleisher LA et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology. 2016;68(10):1082-115. DOI: 10.1016/j.jacc.2016.03.513